Tildrakizumab Market Research Report 2026: $3+ Bn Opportunities, Trends, Competitive Landscape, Strategies, And Forecasts, 2020-2025, 2025-2030F, 2035F

(MENAFN- GlobeNewsWire - Nasdaq) Major opportunities in the tildrakizumab market include the rising demand for personalized autoimmune therapies, expansion of biologic indications, increasing home-based biological administration, and improved healthcare facilities. The market also benefits from growing autoimmune disease incidence and enhanced patient-centric treatment regimens.

Dublin, May 11, 2026 (GLOBE NEWSWIRE) -- The "Tildrakizumab Market Report 2026" has been added to ResearchAndMarkets's offering.

The tildrakizumab market has seen substantial growth, projected to expand from $1.76 billion in 2025 to $1.96 billion in 2026, at a CAGR of 11.7%.By 2030, the market is expected to reach $3.02 billion, maintaining a CAGR of 11.4%.

The Tildrakizumab Market Global Report 2026 is an essential resource for strategists, marketers, and senior management, offering valuable insights into the rapidly growing tildrakizumab market. This comprehensive report highlights key trends that will influence the market over the next decade, offering a robust analysis that can guide strategic decision-making.
The primary drivers of this growth include the increasing prevalence of plaque psoriasis, clinical validation of biologic efficacy, the proliferation of specialty dermatology clinics, rising acceptance of injectable biologics, and improved reimbursement frameworks. Factors fueling this growth encompass a higher demand for personalized autoimmune therapies, augmented biologic indications, focus on long-term disease management, home-based biologic administration adoption, and rising investments in immunology research.

Autoimmune diseases are on the rise due to environmental factors such as pollution, elevating the demand for treatments like tildrakizumab, which targets the IL-23 pathway. Data from Public Health Scotland highlighted a rise in newly diagnosed MS patients, underlining the market's growth potential. Enhanced healthcare facilities are pivotal in supporting market expansion by improving patient access to advanced treatments and ensuring better healthcare provider awareness, as seen in the increase of hospitals reported by the American Hospital Association.

Innovative formulations are key focus areas for market leaders like Sun Pharmaceutical Industries Ltd., which gained approval from the Chinese NMPA for its tildrakizumab injection in treating plaque psoriasis. These advancements target IL-23, thereby reducing inflammation and symptom severity. The market is dominated by players such as Almirall S.A., Novartis, Pfizer, Eli Lilly, and Bristol Myers Squibb, among others.

Geographically, North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region. The countries covered in this market analysis include Australia, Brazil, China, and more, each contributing to the broader regional dynamics in the market.

Key Attributes:

Report Attribute	Details
No. of Pages	250
Forecast Period	2026 - 2030
Estimated Market Value (USD) in 2026	$1.96 Billion
Forecasted Market Value (USD) by 2030	$3.02 Billion
Compound Annual Growth Rate	11.4%
Regions Covered	Global

Report Scope:

Markets Covered:

• Indication: Plaque Psoriasis, Psoriatic Arthritis, Other Indications
• Dosage Form: Injectable, Oral
• Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
• End-User: Hospitals, Specialty Clinics, Homecare

Subsegments:

• Plaque Psoriasis: Moderate, Severe, Treatment-Resistant
• Psoriatic Arthritis: Peripheral, Axial, Enthesitis-related
• Other Indications: Inflammatory Skin Disorders, Off-Label Autoimmune Conditions, Emerging Therapeutic Applications

Companies Featured

• Almirall S.A.
• Sun Pharmaceutical Industries Ltd.
• Novartis
• Pfizer
• Eli Lilly
• Bristol Myers Squibb
• Roche
• Merck & Co
• Janssen Biotech (Johnson & Johnson)
• Amgen
• GSK
• AbbVie
• Sanofi
• AstraZeneca
• Innovent Biologics
• Boehringer Ingelheim
• LEO Pharma
• Kyowa Kirin
• Takeda Pharmaceutical
• Regeneron Pharmaceuticals
• Biocon Ltd.

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN11052026004107003653ID1111097433